Manufacturing

Is H5N1 in Fetal Bovine Serum a New Lab Biosafety Risk?
Biotech & Bioprocessing Is H5N1 in Fetal Bovine Serum a New Lab Biosafety Risk?

Laboratories specializing in virology and immunology must now evaluate if their current biosafety margins are sufficient to protect staff from aerosolized H5N1 exposure. The recent isolation of live, infectious H5N1 avian influenza from a commercial batch of fetal bovine serum (FBS) has sparked a

Can Biomanufacturing Solve the Global Cocoa Crisis?
Management & Regulatory Can Biomanufacturing Solve the Global Cocoa Crisis?

Utilizing brewery-style fermentation tanks to cultivate cocoa cells allows manufacturers to maintain 100 percent supply-chain stability regardless of unpredictable weather patterns. This innovative methodology, pioneered by Boston-based biotechnology leader GALY, arrives at a critical juncture for

How Can Mankind Pharma Balance ESG Growth and Global Scaling?
Management & Regulatory How Can Mankind Pharma Balance ESG Growth and Global Scaling?

The company reported a consolidated revenue of ₹4,031 crore for the first quarter of fiscal year 2027, reflecting a significant 12.89% annual growth. This financial achievement underscores the robust performance of its domestic portfolio, which continues to outpace the general Indian pharmaceutical

What Drives the France Single-Use Bioprocessing Market?
Management & Regulatory What Drives the France Single-Use Bioprocessing Market?

Biopharmaceutical companies in France are utilizing disposable systems to remain competitive by shortening the downtime required between different product batches. This shift represents a fundamental realignment of industrial priorities, moving away from the rigid, permanent infrastructure of the

WuXi Biologics Leads Industry in Sustainable Biopharma Innovation
Management & Regulatory WuXi Biologics Leads Industry in Sustainable Biopharma Innovation

Securing an MSCI AAA ESG rating and an EcoVadis Platinum Medal places WuXi Biologics in the top 1% of companies evaluated for environmental and social governance. This landmark achievement underscores the organization's role as a dominant force in the global healthcare market, particularly as it

Eli Lilly and Novo Nordisk Vie for GLP-1 Market Dominance
Management & Regulatory Eli Lilly and Novo Nordisk Vie for GLP-1 Market Dominance

Although 75 percent of the public believes weight-loss drugs are used for cosmetic reasons, 66 percent still find their use to be socially acceptable in modern society. This fundamental shift in perception coincides with the rise of glucagon-like peptide-1 receptor agonists, which have

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later